Key Takeaways
- • A consortium of three private equity firms—Toscafund Asset Management, Three Hills, and Ares Management—has acquired UK private hospital operator Spire Healthcare for £1.03 billion (£250 per share in cash), representing a 66.2% premium to the May 13 pre-announcement closing price.
- • Spire Healthcare shareholders representing 53.4% of the company's stock have committed to support the offer, with an alternative structure allowing shareholders to exchange up to 8.5% of shares for loan notes at a 2.5x ratio.
- • The deal values Spire's fully diluted equity at approximately £1.03 billion with an enterprise value of £2.31 billion; the acquiring consortium plans to delist Spire from the London Stock Exchange post-acquisition.
- • Paolo Pieri, former chief executive of Circle Health Group, will assume the chair role at the newly formed acquisition vehicle, Tulip UK Bidco, signaling operational leadership transition under new ownership.
- • Spire Healthcare operates 38 hospitals and more than 55 clinics across the UK; the acquisition follows a strategic review launched in September 2025 as the company faced macroeconomic volatility, cost inflation pressures, and evolving payor dynamics.
Summary
Spire Healthcare Group, the UK's largest private hospital chain, has agreed to a £1.03 billion takeover by a consortium comprising funds managed or advised by Toscafund Asset Management, Three Hills Capital, and Ares Management. The transaction, announced over the weekend, offers Spire shareholders 250 pence per share in cash, representing a 66.2% premium to the closing share price on May 13, the last trading day before the possible offer announcement. The deal implies an enterprise value of £2.31 billion on a fully diluted basis.
The board of Spire Healthcare has unanimously recommended the offer to shareholders, citing the company's need to navigate "ongoing challenges of delivering the company's standalone plan against a backdrop of macroeconomic volatility, cost pressures—in particular inflation—and the dynamic nature of the payor environment." Shareholders holding 53.4% of the company's stock have already committed their support, providing substantial backing ahead of the required shareholder vote. The consortium initially made a non-binding offer of 250 pence per share in May 2026, which has now crystallized into a binding agreement.
In addition to the cash consideration, the acquiring consortium has structured an alternative offer allowing shareholders to exchange shares for loan notes issued by Tulip UK Bidco, the acquisition vehicle. This alternative structure is capped at 28 million shares, or 8.5% of scheme shares, with participants receiving 2.5 rollover securities for each Spire share exchanged. This hybrid approach provides shareholders with flexibility in structuring their exit while maintaining some equity upside through the loan note instruments.
Spire Healthcare operates a substantial footprint across the UK healthcare market, with 38 hospitals and more than 55 clinics. The company initiated a strategic review in September 2025 to evaluate options including a potential sale, ultimately concluding that private equity ownership offers the optimal path forward given current market conditions and operational pressures. Following completion of the acquisition, Tulip UK Bidco intends to delist Spire Healthcare from the London Stock Exchange. Paolo Pieri, former chief executive of private healthcare provider Circle Health Group, has been appointed as chair of the acquisition vehicle, bringing relevant healthcare sector expertise to the new ownership structure.
The board of Spire Healthcare has unanimously recommended the offer to shareholders, citing the company's need to navigate "ongoing challenges of delivering the company's standalone plan against a backdrop of macroeconomic volatility, cost pressures—in particular inflation—and the dynamic nature of the payor environment." Shareholders holding 53.4% of the company's stock have already committed their support, providing substantial backing ahead of the required shareholder vote. The consortium initially made a non-binding offer of 250 pence per share in May 2026, which has now crystallized into a binding agreement.
In addition to the cash consideration, the acquiring consortium has structured an alternative offer allowing shareholders to exchange shares for loan notes issued by Tulip UK Bidco, the acquisition vehicle. This alternative structure is capped at 28 million shares, or 8.5% of scheme shares, with participants receiving 2.5 rollover securities for each Spire share exchanged. This hybrid approach provides shareholders with flexibility in structuring their exit while maintaining some equity upside through the loan note instruments.
Spire Healthcare operates a substantial footprint across the UK healthcare market, with 38 hospitals and more than 55 clinics. The company initiated a strategic review in September 2025 to evaluate options including a potential sale, ultimately concluding that private equity ownership offers the optimal path forward given current market conditions and operational pressures. Following completion of the acquisition, Tulip UK Bidco intends to delist Spire Healthcare from the London Stock Exchange. Paolo Pieri, former chief executive of private healthcare provider Circle Health Group, has been appointed as chair of the acquisition vehicle, bringing relevant healthcare sector expertise to the new ownership structure.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.